Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs ESTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AHCO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

AHCO Overall Winner 6-Pillar Tally: AHCO 4 – 2 ESTA Matrix Metrics: AHCO 6 – 4 ESTA

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Establishment Labs Holdings Inc. (ESTA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas ESTA carries 35.7/100 (SELL) at $69.14 (N/M Forward P/E, -6.6% operating margin).

  • Growth vs. Quality Trade-Off: AHCO earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. ESTA 35.7/100 SELL) and 0.17β · 67% Vol risk profile, whereas ESTA leads top-line expansion (+33.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs ESTA
AHCO NASDAQ Head-to-Head Winner
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
ESTA NASDAQ
Establishment Labs Holdings Inc.
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$69.14
-0.68% 1D
Market Cap $2.1B
TTM Revenue $264M
Forward P/E N/M
Beta / 30D Vol 1.49β · 57% Vol
Unified Composite Score
35.7 / 100 SELL
Tech 35.0 Fund 40.0 Flow 61.0 Mom 21.4
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.4 · SMA20: $67.41 · SMA50: $65.69

6-Pillar Scorecard Institutional Category Breakdown (AHCO 4 – 2 ESTA)

Columns: Metric · AHCO · ESTA
1. Valuation Multiples AHCO
Forward P/E 7.8x N/M
Trailing P/E 7.8x N/M
PEG Ratio N/M N/M
EV / Revenue 0.9x 8.6x
2. Growth & Scale ESTA
Revenue Growth (YoY) +10.9% +33.9%
Earnings Growth (YoY) +6.7% +0.0%
TTM Revenue (USD) $3.44B $264M
Market Cap $989.8M $2.1B
3. Profitability & Quality AHCO
Gross Margin 18.2% 70.2%
Operating Margin 3.8% -6.6%
Net Profit Margin -11.8% -14.6%
Return on Equity (ROE) -28.4% -240.7%
4. Balance Sheet & Cash Flow AHCO
Cash Generation (TTM) $82M -$23M
Cash Flow Margin 2.4% -8.8%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $194M Net Debt (17.28x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AHCO
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 66.9% (12th %ile) 58.9% (5th %ile)
Put/Call OI Skew N/A 0.05x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat ESTA
OpEx & R&D Intensity 14.4% of Rev ($495M) 76.8% of Rev ($203M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (6) vs ESTA (4)
Institutional Metric AHCO ESTA Criterion Row Edge
Market Capitalization
Scale
$989.8M $2.1B Larger Scale ESTA
Trailing P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x N/M Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +33.9% Higher Growth ESTA
Operating Margin (TTM)
Profitability
3.8% -6.6% Higher Margin AHCO
Net Profit Margin
Profitability
-11.8% -14.6% Higher Margin AHCO
Return on Equity (ROE)
Capital Efficiency
-28.4% -240.7% Higher ROE AHCO
52-Week Range Position
Momentum
24% ($5–$13) 36% ($53–$98) Stronger Trend ESTA
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 1.49β · 57% Vol Lower Realized Risk ESTA
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 35.7 / 100 (SELL) Higher Composite AHCO
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $264M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 70.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 8.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) -$23M ($194M Net Debt (17.28x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AHCO +7.84 pp
AHCO: +16.69% · ESTA: +8.85%
3M Horizon AHCO +31.94 pp
AHCO: +27.89% · ESTA: -4.05%
6M Horizon ESTA +26.88 pp
AHCO: -31.1% · ESTA: -4.22%
1Y Horizon ESTA +24.32 pp
AHCO: -20.88% · ESTA: +3.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue ESTA Revenue AHCO Op. Margin ESTA Op. Margin Margin Leader
FY2018 $350M $60M 9.0% -39.0% AHCO
FY2019 $530M $90M 5.5% -34.5% AHCO
FY2020 $1.06B $80M 6.8% -33.0% AHCO
FY2021 $2.45B $130M 9.2% -19.8% AHCO
FY2022 $2.97B $160M 6.4% -24.5% AHCO
FY2023 $3.20B $170M -18.7% -39.4% AHCO
FY2024 $3.26B $170M 8.1% -30.1% AHCO
FY2025 $3.24B $210M 2.8% -18.5% AHCO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ESTA CONSOLIDATION
105d in phase · OBV DISTRIBUTION
Current IV 58.9%
IV Percentile 5th %ile
Put/Call OI Skew 0.05x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ESTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
ESTA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.1B market capitalization and -6.6% operating margin.
OpEx & R&D Reinvestment 76.8% of Rev ($203M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs ESTA Key Questions & Quantitative Answers

As of Nov 20, 2026, AdaptHealth Corp. (AHCO) is the stronger overall head-to-head candidate over Establishment Labs Holdings Inc. (ESTA) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas ESTA carries 35.7/100 (SELL) at $69.14 (N/M Forward P/E, -6.6% operating margin). Growth vs. Quality Trade-Off: AHCO earns the overall head-to-head edge with a stronger Unified Composite Score (45.2/100 HOLD vs. ESTA 35.7/100 SELL) and 0.17β · 67% Vol risk profile, whereas ESTA leads top-line expansion (+33.9% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.

ESTA leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with ESTA at +33.9% YoY revenue growth and +0.0% YoY earnings growth on $264M TTM revenue (70.2% gross margin, -6.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while ESTA shifted +250.0%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 76.8% of Rev ($203M) (0 disclosures) for ESTA.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas ESTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 8.6x EV/Revenue (-8.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus ESTA (-240.7% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, ESTA carries 58.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 0.05x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.49β · 57% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.